Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics Previous close 22.22
Open 0.00
Day range —
52-week range 11.20 48.60
Off day high 0.00%
Off 52-week high −54.28%
Volume 2.00
Avg. volume (3M) 110
Market cap 2.30B
EPS (TTM) -16.20
Forward P/E —
P/E ratio (TTM) —
Dividend yield —
Beta (5Y) —
Shares outstanding 103.40M
Short interest —
Earnings date Aug 12, 2026
Analyst target —
Profit margin —
No recent coverage in the 4Search index.
From articles in the 4Search news index.
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.
From Wikipedia , CC BY-SA 4.0
Earnings
Next report: Wed, Aug 12, 2026
Not eligible for Gainers, Losers, Most active (U.S. stocks worth $2 billion or more only).
Not eligible for Small-cap gainers, Aggressive small caps (U.S. stocks worth under $2 billion only).
Not eligible for Growth tech (U.S. technology stocks only).
Not eligible for Undervalued large caps (U.S. stocks worth $10 billion or more only).
A day counts when it ranked in the top 25 of a list. Tracked since Oct 10, 2026.
Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use .